The Antibacterial Resistance Leadership Group: Progress report and work in progress

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S3-S7

  Chambers, Henry F ^a   Cross, Heather R ^b   Evans, Scott R ^c   Kreiswirth, Barry N ^d   Fowler, Vance G ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD UNIVERSITY   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

Antibacterial Resistance; Clinical trials; Diagnostics; Network; Stewardship

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN TROMETAMOL; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL OUTCOME; CLINICAL RESEARCH; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; ENTEROCOCCAL INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KLEBSIELLA PNEUMONIAE; LEADERSHIP; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PUBLIC-PRIVATE PARTNERSHIP; STUDY DESIGN; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; HEALTH SERVICE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; RESEARCH;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, BACTERIAL; HUMANS; LEADERSHIP; RESEARCH REPORT; VOLUNTARY HEALTH AGENCIES;

EID: 85033599895     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw824     Document Type: Article

References (12)

1. Cross HR, Harris A, Aria RM, et al. Transforming concepts into clinical trials and creating a multisite network: the Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S8-12.
2. Huvane J, Komarow L, Hill C, et al. Fundamentals and catalytic innovation: the Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S18-23.
3. Manca C, Hill C, Hujer AM, et al. Leading antibacterial laboratory research by integrating conventional and innovative approaches: the Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S13-7.
4. Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S24-9.
5. Doernberg SB, Lodise T P, Thaden JT, et al. Gram-positive bacterial infections: research priorities, accomplishments and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S24-9.
6. Anderson DJ, Jenkins TC, Evans SR, et al. The role of stewardship in antibiotic resistance: the Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S36-40.
7. Tsalik EL, Petzold E, Kreiswirth BN, et al. Advancing diagnostics to address antibacterial resistance: the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S41-7.
8. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015;61:800-6.
9. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016;62:181-9.
10. Patel R, Tsalik EL, Petzold E, et al. Viewpoint: MASTERMIND-bringing microbial diagnostics to the clinic [manuscript published online ahead of print 7 December 2016]. Clin Infect Dis 2016. pii:ciw788.
11. Tsalik EL, Henao R, Nichols M, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. Sci Transl Med 2016;8:322ra11.
12. Sciarretta K, Røttingen JA, Opalska A, Van-Hengel AJ, Larsen J. Economic incentives for antibacterial drug development: literature review and considerations from the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis 2016;63:1470-4.